We have a diversified and balanced clinical development pipeline that covers multiple therapeutic areas, including CNS, cardiovascular and immunological disorders, as well as orphan diseases.

Compound Mechanism of Action Target Indication Status More information
         
Daridorexant Dual orexin receptor antagonist Insomnia Filing in preparation

Investor webcast (first study)

Investor webcast (second study)
Aprocitentan*  Dual endothelin receptor antagonist Resistant hypertension management Phase 3 Investor webcast
Clazosentan Endothelin receptor antagonist Vasospasm associated with aneurysmal subarachnoid hemorrhage (aSAH) Phase 3 Investor webcast
Lucerastat Glucosylceramide synthase inhibitor Fabry disease Phase 3 Investor webcast
Selatogrel P2Y12 receptor antagonist Suspected acute myocardial infarction Phase 3 in preparation  
Cenerimod S1P1 receptor modulator Systemic lupus erythematosus Phase 2  
ACT-774312 CRTH2 receptor antagonist Nasal polyposis Phase 2  
ACT-539313 Selective orexin 1 receptor antagonist Psychiatric disorders Phase 2 in preparation  
Sinbaglustat
 GBA2/GCS inhibitor Rare lysosomal storage disorders Phase 1 complete  
ACT-1004-1239 - Immunology / Cancer Immunotherapy Phase 1  
ACT-1014-6470 - Immunology Phase 1  
ACT-541478 - CNS Phase 1  


* In collaboration with Janssen Biotech to jointly develop and solely commercialize Idorsia's aprocitentan worldwide.

Neurocrine Biosciences has a global license to develop and commercialize Idorsia's ACT-709478, a novel T-type calcium channel blocker, for the treatment of a rare form of pediatric epilepsy. A Phase 2 study is planned for the second half of 2020.
 
Idorsia has the option to license vamorolone from ReveraGen Inc. and has granted to Santhera Holding Ltd the option to sub-license vamorolone worldwide (except Japan and South-Korea) for all indications.

"At Idorsia I can achieve my mission to help people with unmet medical needs."

Lab Head, Chemistry